Fig. 5: Anti-PD-1 improves tumour growth control of B16F10E-KO. | Nature Communications

Fig. 5: Anti-PD-1 improves tumour growth control of B16F10E-KO.

From: Integrin-αV-mediated activation of TGF-β regulates anti-tumour CD8 T cell immunity and response to PD-1 blockade

Fig. 5

a Growth of B16F10E and B16F10E-KO tumours (****p < 0.0001). Right, weights of tumours recovered at day 14, B16F10E+anti-PD-1 vs. B16F10E-KO+anti-PD-1 (*p = 0.023), B16F10E-KO+isotype vs. B16F10E-KO+ anti-PD-1 (*p = 0.049). Tumour volumes and weights are given as means± SEM (n = 6). Data represent one independent experiment out of five. b Absolute number of CD8+ T cells from B16F10E (n = 16) and B16F10E-KO (n = 18) tumours treated with anti-PD-1 or isotype control (n = 17, B16F10E; n = 19, B16F10E-KO). Data are from five independent experiments (*p = 0.037). c Growth of B16F10E-KO tumours (n = 6). Tumour volumes are given as means ± SEM. Data are from one independent experiment out of two. B16F10E-KO+iso vs. B16F10E-KO+anti-PD-1 (*p = 0.043); B16F10E-KO+anti-PD-1 vs. B16F10E-KO+anti-CD8 (*p = 0.020). d Percentages of KLRG1+ cells in CD8+ T cells from tumours (n = 6) treated with anti-PD-1 or isotype control (*p = 0.043, ****p < 0.0001). Data are from one independent experiment out of three. e Percentages of Ki-67+ T cells among CD8+ (*p = 0.012) and CD69+CD103+CD8+ TIL from B16F10E-KO (n = 6) and B16F10E tumours treated with anti-PD-1 (n = 6) or isotype control (n = 5). Data are from one independent experiment out of three. f Percentages of granzyme B (GzmB)+ (left, **p = 0.0043, ****p < 0.0001) and CD69+CD103+ (middle, *p = 0.025, **p = 0.008) in CD8+ T cells from tumours (n = 6) treated with anti-PD-1 or isotype control. One independent experiment out of three is shown. Right, percentages of granzyme B+ cells in CD69+CD103+CD8+ T cells from B16F10E (n = 11) and B16F10E-KO (n = 12) treated with anti-PD-1 or isotype control (n = 11), B16F10E+iso vs. B16F10E-KO+isotype (*p = 0.046); B16F10E-KO+isotype vs. B16F10E-KO+anti-PD-1 (*p = 0.040). Two independent experiments out of three are included. g. Cytotoxic activity of CD8+ TIL isolated from B16F10E and B16F10E-KO tumours treated with anti-PD-1 or isotype control (*p = 0.037). Indicated are the effector-to-target (E:T) ratios. Data are means of three independent experiments. Each symbol represents an individual tumour; horizontal lines correspond to mean ± SEM (a right, b, d−f.). Data were calculated with one-way ANOVA with Tukey’s correction (a right, d, e, f left, middle), unpaired t-test (b, f right, g.), two-way ANOVA for tumour growth (a, c). Source data are provided as a Source Data file.

Back to article page